Vascular endothelial cells at sites of cell-mediated immune responses show morphological alteration, expression of new antigens and acquisition of new functions. The endothelial activation response may be studied in vitro by addition of specific immune-generated mediators (i.e. lymphokines) to cultured endothelial cells. To date, different mediators have been found to produce distinct but overlapping patterns of activation through the expression of specific genes. The long term goals of this proposal are to fully determine the patterns of activation of endothelial cells by different lymphokines and to delineate the genetic mechanisms of these activation processes. In the proposed experiments, available and de novo generated monoclonal antibodies will be used to define activation patterns; and available and de novo generated cDNA probes will be used to delineate genetic mechanisms. Two specific activation antigens will be studied in detail: the molecule identified by monoclonal antibody H4/18 (an acute activation antigen), and the T cell recognition molecules encoded for by the major histocompatibility complex (which appear to rise with chronic activation). The anticipated results of these studies include the development of a panel of probes (antibody and cDNA) which can be used to analyze endothelial cell activation in vitro and in situ. These experiments should also provide a better understanding of specific activation pathways. Finally, the availability of such reagents and data may suggest new avenues for therapeutic intervention aimed at blocking harmful immune inflammatory episodes through modulation of endothelial cell responses.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL036003-05
Application #
3350460
Study Section
Pathology A Study Section (PTHA)
Project Start
1985-07-01
Project End
1992-06-30
Budget Start
1989-07-01
Budget End
1990-06-30
Support Year
5
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Pierce, Richard W; Merola, Jonathan; Lavik, John Paul et al. (2017) A p190BRhoGAP mutation and prolonged RhoB activation in fatal systemic capillary leak syndrome. J Exp Med 214:3497-3505
Al-Lamki, Rafia S; Wang, Jun; Yang, Jun et al. (2016) Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma. Oncotarget 7:24111-24
Abrahimi, Parwiz; Qin, Lingfeng; Chang, William G et al. (2016) Blocking MHC class II on human endothelium mitigates acute rejection. JCI Insight 1:
Al-Lamki, R S; Lu, W; Manalo, P et al. (2016) Tubular epithelial cells in renal clear cell carcinoma express high RIPK1/3 and show increased susceptibility to TNF receptor 1-induced necroptosis. Cell Death Dis 7:e2287
Clark, Paul R; Kim, Richard K; Pober, Jordan S et al. (2015) Tumor necrosis factor disrupts claudin-5 endothelial tight junction barriers in two distinct NF-?B-dependent phases. PLoS One 10:e0120075
Abrahimi, Parwiz; Chang, William G; Kluger, Martin S et al. (2015) Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ Res 117:121-8
Wang, Jun; Al-Lamki, Rafia S; Zhu, Xinwang et al. (2014) TL1-A can engage death receptor-3 and activate NF-kappa B in endothelial cells. BMC Nephrol 15:178
Pober, Jordan S; Sessa, William C (2014) Inflammation and the blood microvascular system. Cold Spring Harb Perspect Biol 7:a016345
Kluger, Martin S; Clark, Paul R; Tellides, George et al. (2013) Claudin-5 controls intercellular barriers of human dermal microvascular but not human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 33:489-500
Al-Lamki, Rafia S; Lu, Wanhua; Wang, Jun et al. (2013) TNF, acting through inducibly expressed TNFR2, drives activation and cell cycle entry of c-Kit+ cardiac stem cells in ischemic heart disease. Stem Cells 31:1881-92

Showing the most recent 10 out of 82 publications